http://www.fpnotebook.com/
Nucleoside Reverse Transcriptase InhibitorAka: nRTI, Double nRTI
- Mechanism
- Incorporate into DNA of virus
- Stops building process
- Resulting DNA incomplete, cannot create new virus
- Preparations
- Abacavir (Ziagen)
- Didanosine (Videx, ddI)
- Lamivudine (Epivir, 3TC)
- Stavudine (Zerit, d4T)
- Zalcitabine (Hivid, ddC)
- Zidovudine (Retrovir, ZDV or AZT)
- Abacavir, Lamivudine, and Zidovudine (Trizivir)
- Lamivudine and Zidovudine (Combivir)
- Double nRTI Combinations
- Stavudine (d4T) and Didanosine (ddI)
- Consider with Hydroxyurea 500 bid
- Stavudine (d4T) and Lamivudine (3TC)
- Zidovudine (AZT) and Didanosine (ddI)
- Zidovudine (AZT) and Zalcitabine (ddC)
- Zidovudine (AZT) and Lamivudine (3TC)
- Stavudine (d4T) and Didanosine (ddI)
- Adverse Reactions
- Neuropathy (occurs with 3 D's: DDI, DDC, D4T)
- Didanosine (ddI)
- Zalcitabine (ddC)
- Stavudine (d4T)
- Pancreatitis (occurs with 3 D's: DDI, DDC, D4T)
- Didanosine (ddI)
- Zalcitabine (ddC)
- Stavudine (d4T)
- Hepatomegaly and Steatosis
- Lactic Acidosis (uncommon, but life-threatening)
- Stop nRTI immediately if Lactic Acidosis occurs
- Associated with prolonged nRTI use
- More common in overweight and pregnant women
- Severe lethal Hypersensitivity Reaction
- Abacavir (occurs on rechallenge after reaction)
- Gastrointestinal upset or Diarrhea
- Neuropathy (occurs with 3 D's: DDI, DDC, D4T)
Nucleoside Reverse Transcriptase Inhibitors (C1373111) | |
|---|---|
| Concepts | Pharmacologic Substance (T121) |
| English | Nucleoside Reverse Transcriptase Inhibitors |
| Parent Concepts | Reverse Transcriptase Inhibitors (C0282519) |
| Sources | NDFRT Derived from the NIH UMLS (Unified Medical Language System) |